Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

ADARx Pharmaceuticals Q3 2026 Results: Net Loss of $28.1M, Loss Widens

ADARx Pharmaceuticals reported a significant increase in cash and cash equivalents to $570.6 million as of September 30, 2026, following its initial public offering and concurrent private placement. The company is advancing a clinical pipeline including onvuzosiran (Phase 3) and agazisiran (Phase 2), supported by a major collaboration with AbbVie that contributed to $326.4 million in total deferred revenue.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue2.21.6
Net income-28.1-17.9
EPS (diluted, $ a share)$-1.74$-1.85

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+42.6%
Source

10-Q filed with the SEC, NASDAQ: ADRX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

ADARx Pharmaceuticals, Inc.: key numbers

Share price
$14.00Close, Nov 16
Market cap
$1.56B
Shares outstanding
111.19MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from ADARx Pharmaceuticals, Inc.

All →
4:07 PM ET 8-K
Financial Results

ADARx Pharmaceuticals Financial Results

ADARx Pharmaceuticals reported Q3 2026 financial results, highlighting a cash position of $611.8 million following its IPO and concurrent private placement with AbbVie. The company is advancing three Phase 2 clinical trials for agazisiran and received FDA Fast Track designation for onvuzosiran in hereditary angioedema.

“We have made significant progress across our pipeline of next-generation siRNA therapeutics, bolstered by the successful completion of our IPO and concurrent private placement. These financings provide the resources to advance three clinical-stage programs in parallel, bring two advanced preclinical candidates into the clinic, and support additional IND filings as we expand our pipeline.”

Zhen Li, Ph.D., President and Chief Executive Officer of ADARx

“As the siRNA field evolves, we see tremendous opportunity to expand the range of diseases these therapeutics can address. We believe that our progress with differentiated liver-targeted programs and targeted delivery to extrahepatic tissues positions us to advance our mission of delivering life-changing treatments to patients with unmet medical needs.”

Zhen Li, Ph.D., President and Chief Executive Officer of ADARx
5:30 PM ET Form 4
Insider Buying

ADARx Pharmaceuticals Insider Erez Chimovits Buys $1.05M of Stock

Erez Chimovits bought 61,516 shares of ADARx Pharmaceuticals, Inc. at $17.00 a share, worth $1.05M in total on Sep 28, 2026. Shares held after the trade: 9,292,025 (+0.7%).

Value
$1.05M
Shares
61,516
Price
$17.00
Holding change
+0.7%
Trade date
Sep 28, 2026
5:26 PM ET Form 4
Insider Buying

ADARx Pharmaceuticals Insider Carl L. Gordon Buys $16.1M of Stock

Carl L. Gordon bought 950,000 shares of ADARx Pharmaceuticals, Inc. at $17.00 a share, worth $16.1M in total on Sep 28, 2026. Shares held after the trade: 9,292,025 (+0.7%).

Value
$16.1M
Shares
950,000
Average price
$17.00
Holding change
+0.7%
Trade date
Sep 28, 2026
5:23 PM ET Form 4
Insider Buying

ADARx Pharmaceuticals Insider Orbimed Advisors LLC Buys $16.1M of Stock

Orbimed Advisors LLC bought 950,000 shares of ADARx Pharmaceuticals, Inc. at $17.00 a share, worth $16.1M in total on Sep 28, 2026. Shares held after the trade: 9,292,025 (+0.7%).

Value
$16.1M
Shares
950,000
Average price
$17.00
Holding change
+0.7%
Trade date
Sep 28, 2026
2:20 AM ET Form 4
Insider Buying

ADARx Pharmaceuticals Director Simeon George Buys $27.2M of Stock

Simeon George, Director, bought 1,600,000 shares of ADARx Pharmaceuticals, Inc. at $17.00 a share, worth $27.2M in total on Sep 28, 2026. Shares held after the trade: 592,593.

Value
$27.2M
Shares
1,600,000
Average price
$17.00
Role
Director
Trade date
Sep 28, 2026
2:20 AM ET Form 4
Insider Buying

ADARx Pharmaceuticals 10% Owner Sr One Capital Management LLC Buys $27.2M of Stock

Sr One Capital Management LLC, 10% Owner, bought 1,600,000 shares of ADARx Pharmaceuticals, Inc. at $17.00 a share, worth $27.2M in total on Sep 28, 2026. Shares held after the trade: 592,593.

Value
$27.2M
Shares
1,600,000
Average price
$17.00
Role
10% Owner
Trade date
Sep 28, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.